Post

New research · Internal Medicine
Metabolism: clinical and experimental · 3h
Cohort studyMetabolism: clinical and experimental · 2026

Complementary body weight and cardiometabolic benefits of higher GLP-1 and lower GIP: Genetic evidence from large-scale phenomic analyses.

Lijuan Wang, Fangyuan Jiang, Shuai Yuan … Christos S Mantzoros
Read paper
Internal MedicineCohort study

Genetically higher GLP-1 plus lower GIP levels linked to lower obesity risk

Complementary body weight and cardiometabolic benefits of higher GLP-1 and lower GIP: Genetic evidence from large-scale phenomic analyses.

Lijuan Wang … Christos S Mantzoros
Metabolism: clinical and experimental · 2026
Background

The long-term health effects of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) remain unclear.

Methods

TreeWAS was first conducted to map associations of GLP-1 or GIP levels with a broad range of disease outcomes among 385,917 UK Biobank participants.

Results

genetics tied to more GLP-1 and less GIP lowered obesity risk

HR by subgroup · 95% CI
null = 1
obesity
0.93
CVD
0.97
More results

TreeWAS analysis revealed associations of elevated genetically predicted GLP-1 levels, even within the normal range, with decreased risk of metabolic diseases (e.g. type 2 diabetes) and polyarthropathies (e.g. gout).

More results

While genetically determined low GIP levels were linked to reduced risk of obesity, metabolic diseases (e.g. disorders of lipoprotein metabolism and other lipidaemias), digestive/hepatic and cardiometabolic diseases.

“
Conclusion

Our genetic findings are consistent with the hypothesis that GLP-1 levels in the higher physiological range and GIP levels in the lower physiological range, individually and jointly, may be associated with lower body weight and improved cardiometabolic and liver phenotypes, while these observations warrant mechanistic and clinical investigation.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
0.8%
an oversedation event needing naloxone reversal was rare
Randomized Trial
t = -4.35
intervention caregivers asked more questions than controls
Cohort Study
67.8%
one-year survival was far worse than the intermediate-risk group's, roughly one in three died
Review
50-100%
rheumatoid arthritis raises blood clot risk well above the general population
Cross-sectional
SIR 9.93
risk climbs sharply when relatives cluster and clotting starts young
Study
82.5%
guideline-recommended anticoagulation reached most hospitalized af patients after screening
Study
7.74
Average knowledge score rose from 5.24 to 7.74 after the education intervention
Cohort Study
34.4%
just over a third stayed safely anticoagulated, most were not